Tonix Pharmaceuticals Files 8-K
Ticker: TNXP · Form: 8-K · Filed: Dec 23, 2024 · CIK: 1430306
Sentiment: neutral
Topics: corporate-info, filing
Related Tickers: TNXP
TL;DR
TNXP filed an 8-K updating corporate info, offices in Chatham, NJ.
AI Summary
Tonix Pharmaceuticals Holding Corp. filed an 8-K on December 23, 2024, reporting on other events and financial statements. The filing indicates the company's principal executive offices are located at 26 Main Street, Suite 101, Chatham, NJ 07928, with a business phone number of (862) 277-0577. The company was formerly known as Tamandare Explorations Inc. before a name change on March 20, 2008.
Why It Matters
This filing provides updated corporate information and location details for Tonix Pharmaceuticals Holding Corp., which is relevant for investors and stakeholders tracking the company's official presence and administrative details.
Risk Assessment
Risk Level: low — This filing is primarily administrative and updates corporate information, posing no immediate financial or operational risk.
Key Players & Entities
- Tonix Pharmaceuticals Holding Corp. (company) — Registrant
- December 23, 2024 (date) — Filing Date
- 26 Main Street, Suite 101, Chatham, NJ 07928 (location) — Principal Executive Offices
- Tamandare Explorations Inc. (company) — Former Company Name
- March 20, 2008 (date) — Date of Name Change
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on other events and financial statements, as well as to update corporate information for Tonix Pharmaceuticals Holding Corp.
Where are Tonix Pharmaceuticals Holding Corp.'s principal executive offices located?
Tonix Pharmaceuticals Holding Corp.'s principal executive offices are located at 26 Main Street, Suite 101, Chatham, New Jersey 07928.
What was Tonix Pharmaceuticals Holding Corp. formerly known as?
Tonix Pharmaceuticals Holding Corp. was formerly known as Tamandare Explorations Inc.
When did the company change its name from Tamandare Explorations Inc.?
The company changed its name from Tamandare Explorations Inc. on March 20, 2008.
What is the SEC file number for Tonix Pharmaceuticals Holding Corp.?
The SEC file number for Tonix Pharmaceuticals Holding Corp. is 001-36019.
Filing Stats: 815 words · 3 min read · ~3 pages · Grade level 12.9 · Accepted 2024-12-23 08:05:23
Filing Documents
- tnxp-8k_122324.htm (8-K) — 30KB
- ex99-01.htm (EX-99.01) — 28KB
- 0001999371-24-015671.txt ( ) — 240KB
- tnxp-20241223.xsd (EX-101.SCH) — 3KB
- tnxp-20241223_lab.xml (EX-101.LAB) — 33KB
- tnxp-20241223_pre.xml (EX-101.PRE) — 24KB
- tnxp-8k_122324_htm.xml (XML) — 3KB
01
Item 7.01 Regulation FD Disclosure. On December 23, 2024, Tonix Pharmaceuticals Holding Corp. (the "Company") announced that the U.S. Food and Drug Administration ("FDA") assigned a Prescription Drug User Fee Act ("PDUFA") goal date of August 15, 2025 for a decision on marketing approval for its TNX-102 SL (cyclobenzaprine HCl sublingual tablets) product candidate for the management of fibromyalgia. A copy of the press release which discusses this matter is furnished hereto as Exhibit 99.01, and incorporated herein by reference. The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.01 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 Other Events
Item 8.01 Other Events. On December 23, 2024, the Company announced that the FDA assigned a PDUFA goal date of August 15, 2025 for a decision on marketing approval for TNX-102 SL. Forward- Looking Statements This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking and management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the SEC. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibit No. Description. 99.01 104 Press Release of the Company, December 23, 2024 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. TONIX PHARMACEUTICALS HOLDING CORP. Date: December 23, 2024 By: /s/ Bradley Saenger Bradley Saenger Chief Financial Officer